GlassScriptPhysician profile
Ibrahim Ahmad
NPI 1649278110
$231,688.13
in general payments reported to CMS, 2019-2025
29 companies · $20K in 2025
The $20K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $64K · 2020: $25K · 2021: $36K · 2022: $54K · 2023: $29K · 2024: $3,635 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $40K · Consulting Fee: $4,674 · Travel and Lodging: $3,911 · Food and Beverage: $3,683 · Education: $264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $40,098.50 |
| Consulting Fee | $4,674.00 |
| Travel and Lodging | $3,911.38 |
| Food and Beverage | $3,683.25 |
| Education | $263.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $114,827.96 | 2019-2024 | Jynarque |
| Astrazeneca Pharmaceuticals LP | $47,078.24 | 2019-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $30,785.93 | 2021-2025 | |
| Vifor Pharma, INC. | $22,375.43 | 2019-2023 | Veltassa, Korsuva |
| Akebia Therapeutics INC | $12,167.59 | 2020-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $1,728.39 | 2021-2023 | Benlysta |
| Opko Pharmaceuticals, LLC | $471.83 | 2019-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $329.28 | 2019-2025 | Velphoro, Velphoro |
| Ardelyx, INC. | $327.08 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Novartis Pharmaceuticals Corporation | $286.55 | 2024-2025 | |
| Amgen INC. | $267.14 | 2019-2025 | Tavneos, Krystexxa |
| Calliditas Therapeutics US INC. | $150.57 | 2023-2025 | Tarpeyo |
| Travere Therapeutics, INC. | $131.34 | 2021-2025 | |
| Horizon Therapeutics Plc | $119.55 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $93.07 | 2022-2024 | Lupkynis |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $86.32 | 2020 | |
| Daiichi Sankyo INC. | $79.88 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $64.51 | 2019 | |
| Scpharmaceuticals INC. | $42.36 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.13 | 2024 | Jardiance |
| Mallinckrodt Enterprises LLC | $34.53 | 2019 | |
| Renalytix Ai, INC. | $32.36 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Alexion Pharmaceuticals, INC. | $32.16 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.95 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $27.00 | 2021 | |
| Novo Nordisk INC | $24.37 | 2023 | Ozempic |
| Lilly USA, LLC | $18.72 | 2024 | Jardiance |
| Idorsia Pharmaceuticals US INC | $18.06 | 2023 | Quviviq |
| Hikma Pharmaceuticals USA | $16.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.